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Abstract
Background: Sub-Saharan African countries are plagued by an
adaptable parasite, Trypanosoma brucei, T.b., with a very high iron
dependency. This protozoan parasite is the causative agent for
Human African Trypanosomiasis (HAT), otherwise known as
sleeping sickness. Two specific subspecies of interest include T.b.
gambiense and T. b. rhodesiense. They lead to either a chronic or
acute form of the fatal sleeping sickness disease, respectively. Few
effective methods of treatment are available. The goal of this
research project is to propose pharmaceutical drug target(s) to
combat T. brucei infections. Methods: Studies analyzed the
reaction pathways that take place during the parasite’s life cycle,
identified the natural and chemically produced superoxide radicals
within the parasite, and also elucidated the differences in the
parasite’s life processes will allow for the derivation of a plausible
methods to cease the infection cycle of the T. brucei parasite. The
impact of these factors on preventing or reducing the virulence of the
infection by T. brucei was assessed using computer-aided simulation
software named CLEMS, Command-Line Electro-Metabolomics
Software. We monitored the concentrations of oxygen, glucose and
dihydroxyacetone phosphate, DHAP, given their importance for the
survival of the parasite. Oxygen concentration peaked soon after the
start of the simulation before achieving steady state with a
concentration comparable to that of the mammalian environment
simulated; glucose concentration was constant throughout the
simulation again consistent with the environment where the parasite
is evolving; finally, results showed a decrease in DHAP
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concentration followed by steady state. Any process, which
contributes to further decreasing DHAP concentration, is likely to be
detrimental to the T. brucei. Other processes, such as superoxide
radical degradation, will be considered in concert to the ones
assessed in this study to develop suitable drug targets.

Introduction
Native to Sub Saharan African countries, the tsetse fly carries and
transmits a fatal and often neglected tropical disease, Human African
Trypanosomiasis, or HAT. This deadly disease affects at least 30
African countries.1 The country with the highest infection rate is the
Democratic Republic of Congo.2 Of note, the number of reported
cases of Trypanosoma brucei gambiense infections, which are
chronic, is extremely higher than those of T. b. rhodesiense, which
are acute. However, neither of these subspecies morphologically
differs from one another.
The transmission route and life cycles are also important. A tsetse fly
will ingest the parasite where it is transported to the gut. The parasite
is then in the procyclic form while inside the fly. Once the fly is
infected, the insect becomes a vector of transmission for the disease
until the end of its life. When the infected fly bites a human, it
transfers the parasite directly into the human’s bloodstream. Once in
the bloodstream, the T. brucei parasite converts to the bloodstream
form and circulates throughout the host’s blood vessels and tissues.3
In this form, the parasite spreads to important mammalian fluids
including: lymph and cerebrospinal fluid, along with those found in
the placenta.2 Symptoms include, but not limited to, fever, severe
headaches, irritability, extreme fatigue, swollen lymph nodes and
aching muscles and joints. The disease is diagnosed by finding the
parasite in body fluid or tissue by microscopy.4
Current treatment options have certain limitations or harmful effects
associated with each option. Certain drugs do not combat both the
haemo-lymphatic and the meningo-encephalic stages of the sleeping
sickness, all the while T. brucei has already begun to grow resistant
to some treatments. Therefore, the need for a drug target that can
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inhibit parasitic functions, preferably through distinct and parasitespecific reaction pathways inhibition, has increased in recent years.
Moreover, T. brucei possesses several unique characteristics that
increase its survival rates. Naturally, every organism is comprised of
multiple defense mechanisms. T. brucei is equipped with four
superoxide dismutases—all requiring an iron, Fe, metal cofactor.
Superoxide dismutases, SODs, are antioxidants used in the parasite’s
defense mechanism to rid itself of radicals via dismutation of
superoxide radicals into hydrogen peroxide and molecular oxygen.5
This particular mechanism has been the target of many drug
treatments (table 1).
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Table 1 Existing Treatment Options for HAT: Available
drug treatments for HAT along with possible side effects.
Known structures are depicted as to facilitate future
docking studies.
Drugs

Stage of
Disease

Strain

NECT
nifurtimoxeflornithine
combination
therapy

Central
Nervous
System
Stage

Gambiense

Nifurtimox used in
treat of Chagas
disease

Pentamidine

Circulator
y Stage

Gambiense

Side effect: effects on
the pancreas

Eflornithine

Central
Nervous
System
Stage

Gambiense

Side effect:
Hematologic
abnormalities,hearing
loss,
Thrombocytopenia

Melarsoprol

Central
Nervous
System
Stage

Rhodesiense

Arsenic derivative
Side effect:
Convulsions, fever,
loss of consciousness,
rashes, bloody stools,
nausea, and vomiting.
Encephalopathy

Suramin

Additional Info

Structure

Side effects:
rashes,adrenal
Circulator Gambiense and
cortical damage,
y Stage
Rhodesiense
kidney damage
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T. brucei, receives all of its energy from glycolysis. This glycolysis
cycle differs from other eukaryotes in that glycolysis is T. brucei’s
sole ATP-producing process.6 The parasite metabolizes the glucose
readily available in the host’s bloodstream converting it into
pyruvate. The first seven steps occur in the glycosome, a part of the
cell with functions similar to peroxisomes.6 Other eukaryotes carry
out the process in the cell’s cytosol. This peculiarity makes T.
brucei’s glycolysis mechanisms one of the main foci for drug target
analysis.6,7 In addition, the parasite’s glycolytic process can occur
under both aerobic and anaerobic conditions. Some factors
facilitating the parasite’s adaptability include, yet not limited to:
changes in coat surface and antigenic variation. The parasite exhibits
antigenic variation, which is a switch in expression of variable
surface glycoproteins, VSG, genes that encodes VSG coats.3 These
thick coats protect the parasite from immune system attacks. T.
brucei has multiple VSG genes, only expressing them one at a time.3
This particular adaptability contributes to the parasite’s ability to
bypass immunological responses and allows it to multiply in the
mammalian bloodstream and eventually cross the blood-brain
barrier. Unfortunately, minimal information is available on exact
pathways during this switching process, and therefore much research
is still needed. Current literature reveals that there are five existing
treatment options for HAT (Table 1), and of the five some are either
toxic to the host, too expensive for administration, or fails to address
the infection in its entirety.
Chemotherapeutic drugs treat the disease by inducing oxidative
stress (Table 1). A component of the most readily accepted treatment
option, NECT, Nifurtimox leads to the formation of reactive oxygen
species otherwise referred to as ROS.8 The drug can be orally
administered and is readily absorbed throughout the body crossing
the blood-brain barrier.9 Eflornithine, the other component of NECT
combats the meningo-encephalic stage in T. b. gambiense infection
but is ineffective against T. b. rhodesiense. The demand for a new
pharmaceutical drug to combat sleeping sickness increases each day
as the parasitic infection persists. To contribute to this search and
study, computational modeling methods were used to assess impacts
of reaction pathway disruptions. We simulated the glycolytic and the
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superoxide radical degradation pathways of the parasite within the
mammalian oxic environment.7,10 We monitored the concentrations
of oxygen, glucose and DHAP as these represent three of the most
important compounds that T. brucei relies on for survival.

Materials and Methods
Mathematically derived models of reaction pathways were
developed and utilized for computer simulation. Reaction kinetics
data was obtained through extensive literature review. The parasites’
dire need for iron and the occurrence of free radicals due to the
superoxide radical degradation pathway are pertinent to the
discovery of the pharmaceutical drug target to annihilate the parasite
without harming the hosts. The superoxide radical degradation
pathway acts like the electron transport chain, severing oxygen
molecules resulting in extremely reactive oxygen radicals.
Manipulating a reaction’s pathway to produce reactive oxygen
radicals would in turn cause the parasite to self-destruct.
Chokepoints, which are metabolites at the end of a metabolic process
used as in other reactions pathways, constitute a major aspect in
developing an improved drug target. Thus, they were followed
closely throughout the simulation. Enzymatic activities of the
multiple biochemical and electrophysiological species of the parasite
were accounted for with specific Michaelis-Menten parameters. The
formula:
ℎ=

𝑉𝐾𝑌
𝐴𝐾 𝐾 + 𝑐 + 𝑐 ! + 𝐴𝜃𝑐𝑐 !

provides a four-state model for a facilitated diffusion carrier. In the
above equation, h is the parameter that quantifies how fast the
species can navigate the membrane, V is the maximum rate of
exchange of species between compartments, K is the MichaelisMenten constant describing transport properties between
compartments, c and c’ are respective concentrations, and θ is the
symmetry index between compartments. The value for θ can vary
between the integers 0 and 1.1
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Reactions that occur in the same cellular region or share some
common species were classified, organized, and their kinetic values
were computed. In addition, reactions were designated as either slow
or fast, i.e. equilibrated. In the glycolysis pathway, 41 slow reactions
that are taking places in three separate cell compartments were
recorded and analyzed. The ATP-producing process that converts 2
moles of glucose into 2 moles of pyruvate is extremely intricate.
Without the proper transportation of every compound and element,
T. brucei suffers. Hence, proper identification of the location of each
step in the process proves pertinent to calculations. The
transportation of charged and rather large metabolites across an
impermeable membrane dictates the usage of transporters. The
transport of species against their gradients indicates active diffusion,
which was modeled also in the simulation. The reactions were
written in accordance to the mechanisms of the pathway.
Parameters, such as maximum transport rate of a species from
compartment to compartment, Michaelis-Menten constants,
stoichiometry of reactions, and other specifications were calculated
and calibrated, where information was incomplete, to give final
concentrations of each species. Once all of the data was obtained and
computed, the information was input into the CLEMS software (Max
Fontus, Cypress, TX), where numerical datasets describing species
concentrations at multiple time steps were produced. CLEMS
generates quantitative data by converting biochemical and
electrophysiological information into ordinary differential equations,
which are then solved numerically.
All initial information was compiled1,7 in a master list containing
species name, molecular weight, formal charge, and chemical
symbol; each species was assigned a numerical value within the
simulation (Table 2). Throughout the simulations, different
environments and conditions can be easily assessed and according
results investigated.
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Table 2 Species Master List: These are the species
involved in the five known important pathways of T.
brucei. The associated charged of the species are also
tabulated when reported in the literature or based on the pH
level of the compartment where they are located in the
course of a simulation. The charges in the parentheses are
reflective of the fact that multiplicity of charges is possible
based on pH
Species Name
Dihydroxyacetone
phosphate (DHAP)
Glucose
Glucose 6 phosphate
(Glc-6-P)
Fructose 6 phosphate
(Fru-6-P)
Fructose 1,6-bisphosphate
(Fru-1,6-BP)
Glyceraldehyde
3-phosphate (GA-3-P)
1,3-bisphosphoglycerate
(1,3-BPGA)
3-Phosphoglycerate (3PGA)
2-Phosphoglycerate (2PGA)
Glycerol 3-Phosphate
(Gly-3-P)
Phosphoenolpyruvate
(PEP)
Fructose 2,6-bisphosphate
(F26BP)
Hexokinase (HK)
Phosphoglucose
Isomerase (PGI)
Phosphofructokinase
(PFK)
Aldolase (Ald)
Triose Phosphate
Isomerase (TIM)
Phosphoglycerate Kinase
(PGK)

ISSN: 2473-6201

1

Chemical
Symbol/
formula
C3 H7 O6 P

2
3

C6H12O6
C6H13O9P

0
0(-2)

180.16
260.16

4

C6H13O9P

0(-2)

259.81

5

C6H14O12P2

0(-4)

340.116

6

C3 H7 O6 P

0(-2)

170.058

7

C3H8O10P2

0(-4)

266.03

8

C3 H7 O7 P

0(-2)

186.06

9

C3 H7 O7 P

0(-2)

186.06

10

C3 H9 O6 P

0(-2)

172.074

11

C3 H4 O6 P

-1(-3)

167.034

12

C6H14O12P2

0(-4)

340.116

13
14

Enzyme
Enzyme

15

Enzyme

16
17

Enzyme
Enzyme

18

Enzyme

Species
number

32

Charge

MW
(g/mol)

0(-2)

170.06
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Table 2 Continued

Glycerol 3-Phosphate
Dehydrogenase (G3PDH)
Glycerol Kinase (GK)
Adenylate Kinase (AK)
AMP-activated Protein
Kinase (AMPK)
Glyceraldehyde 3Phosphate Dehydrogenase
(GAPDH)
Pyruvate Kinase
Glycerol 3-Phosphate
Oxidase (GPO)
Enolase (ENO)
Adenosine Triphosphate
(ATP)
Adenosine Diphosphate
(ADP)
Adenosine
Monophosphate (AMP)
Cyclic Adenosine
Monophosphate (cAMP)
Hydrogen Gas, H2
Proton, H+
Sodium ion, Na+
Potassium ion, K+

19

Chemical
Symbol/
formula
Enzyme

20
21
22

Enzyme
Enzyme
Enzyme

23

Enzyme

24
25

Enzyme
Enzyme

26
27

Enzyme
C10H16N5O13P3

-4(-3)

507.18

28

C10H15N5 O10P2

-3

427.201

29

C10H14N5 O7P

-2

347.22

30

C10H12N5 O6P

-1

329.206

31
32
33
34

H2
H+
Na+
K+

0
+1
+1
+1

2.016
1.008
22.990
39.098

Chlorine ion, ClOxygen gas, O2
Water, H2O
Nicotinamide Adenine
Dinucleotide, NAD+
Reduced Nicotinamide
Adenine Dinucleotide,
NADH
Pyruvate (Pyr)
Glycerol (Gly)
Inorganic Phosphate, Pi
Phosphoglycerate
Mutase (PGM)
Ald-FBP

35
36
37
38

ClO2
H2 O
C21H27N7O14P2

-1
0
0
-1

35.453
31.998
18.015
663.43

39

C21H28N7O14P2

-2

664.44

40
41
42

C3 H4 O3
C3 H8 O3
PO4

-1
0
-1

88.06
92.09
82.16

43

Enzyme

Species Name
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MW
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Table 2 Continued
Species Name
Ald-DHAP
END
G3PDH-NAD
EGN
ESTE
PAP
ATP-PyK
GAG
ATP-GK
PHD
PHA
PAMBG
ATP-PGK
PAMF
ADP-PFK
ESTPi
HGAM
ADP-HK
ATP-HK
ATP-PFK
G3PDH-NADH
ADP-GK
PFKna
ADP-PGK
ADP-PyK
GAPDH-GAP
PHA*
Nicotinamide adenine
dinucleotide phosphate
(NADP+)
Reduced Nicotinamide
adenine dinucleotide
phosphate (NADPH)
6-Phosphogluconolactone (6PGL )
6-Phosphogluconate (6-PG)
Ribulose 5-phosphate (Rul-5P)
Ribose 5-phosphate
Carbon dioxide (CO2)

ISSN: 2473-6201

Species
number

Chemical
Symbol/
formula

Charge

MW
(g/mol)

744.413

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72

C21H29N7O17P3

-3

73

C21H29N7O17P3

-4

74

0

75

0

76

C5H11O8P

+1

230.11

77
78

C5H11O8P
CO2

+1
0

230.11
44.01

34
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Table 2 Continued
Species Name
Trypanothione disulfide
(TS2)
Trypanothione [T(SH)2]
Ribose (Rib)
Superoxide
Hydron,H+
Hydrogen peroxide
Oxygen
Iron Superoxide Dismutase
Superoxide Dismutase

Species
number

Chemical
Symbol/
formula

Charge

MW
(g/mol)

79

C27H47N9O10S2

0

721.84

80
81
82
83
84
85
86
87

C27H49N9O10S2
C5H10O5
O2-1
H+
H2 O2
O2
Enzyme
Enzyme

-1
+2
-1
+1
0
0

723.86
150.13
32
1.008
3.015
16

Results

Concentration
(M)

Many species’ concentrations oscillate until equilibrium is achieved.
It can be observed that in glycolysis, the concentration of oxygen
increases until it peaks, then decreases until steady state is achieved
(figure 1). Oxygen is available in all compartments of the cell at all
times, which would explain the major rise in the concentration until
equilibrium is reached. Glucose concentration was constant, which is
consistent with the fact that the mammalian host environment has a
steady glucose concentration so that the parasite has a continuous
source of metabolic fuel.

Glycosome Concentrations during Glycolysis

5.00E-04

Glucose

1
6
11
16
21
26
31
36
41
46
51
56
61
66
71
76
81
86
91
96
101
106
111
116

0.00E+00

Oxygen

Time (s)

Figure 1 Concentrations of Oxygen and Glucose in the
glycosome during a simulated glycolysis taking place in the
mammalian bloodstream. These numbers were comparable
to that of Navid1,7
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Concentration
(M)

PURSUE

2.00E-02

DHAP

0.00E+00

1
9
17
25
33
41
49
57
65
73
81
89
97
105
113

1.00E-02

Time (s)
Figure 2 Concentration of DHAP in the glycosome during
glycolysis where the conditions are the same as figure 1

The behavior of DHAP was monitored, given its importance in the
anoxic, as well as anoxic, developmental conditions for the parasite.
The obtained behavior of DHAP differed slightly from other factors.
It started out almost constant; it then decreased until the
concentration reached equilibrium between 5.00e-3 and 6.00e-3 M
(figure 2). Any process contributing to further decrease in the
concentration of DHAP would likely prove to be detrimental to the
parasite.
Separate trials were run to validate the software by comparing its
results to experimental historical data. Glycolysis was simulated by
itself, but later on simulations involving glycolysis and the
superoxide degradation pathway were done (Results not shown).
This was designed to address the intertwining network of pathways
T. brucei utilized to survive in multiple environments.

Conclusions
Glycolysis and superoxide radical degradation pathways were
simulated in a computational environment based upon data from
published literature. Given the importance of glycolysis, the
parasite’s sole ATP production process, and the superoxide radical
degradation pathway, a chokepoint related to both pathways is
believed to present and would be an ideal options for pharmaceutical
drug target(s). This putative data confirms that inhibition of
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glycolysis would lead to the destruction of T. brucei. Examination of
additional chokepoints specific to each pathway is underway.
SODs are a major component of the defense mechanism in T. brucei.
Analysis of the biochemical and molecular properties of mechanisms
similar to the superoxide degradation pathway within the parasite is
expected to provide better insights and holds promise for improved
treatment intervention.
Unfortunately, HAT is a neglected disease in that it is not studied as
much and subsequent studies tend to be unorganized. Specifics about
the parasite in both life stages are not readily available and thusly
cannot be used as part of the master input file, leading to an obvious
limitation. However, having a fully functional and consistent
electrophysiological model for T. brucei’s pathways and metabolism
is of great significance. The parasite’s high adaptability provides
many such pathways and characterizes its greatest defense
mechanism. Therefore, modeling other pertinent pathways taking
place in T. brucei will expand and improve results from this project.
With this tool, proposed mechanism(s) can be simulated for
relevance. Once a mechanism is assessed, a target can be
hypothesized. Drugs can be developed and simulated so that their
capacity to eliminate or reduce infectivity, without negatively
affecting the human host, can be studied well in advance of animal
or human clinical trials.
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